ReviewArthritis care & research2026
Physician-Scientist Pipeline for Pediatric Rheumatology: The Current Landscape and Future Perspectives.
Review in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 50 years, the science of pediatric rheumatology has grown exponentially due to an expansion in the understanding of complex rheumatic conditions and a surge in novel targeted therapeutics. Physician-scientists in the field of pediatric rheumatology have played major roles in these advancements that have improved the care of children, adolescents, and young adults with chronic and often life-threatening systemic inflammatory diseases. Despite the critical role of the physician-scientist in discovering and translating scientific advancements from the bench to the bedside and vice versa, which have catapulted the field of pediatric rheumatology, this role remains an endangered species, with a declining pipeline due to a variety of factors. In this article, we review the current landscape of the physician-scientist pipeline for pediatric rheumatology on the fiftieth anniversary of the formalization of the specialty in North America. We review challenges to maintaining a thriving physician-scientist pipeline and discuss future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.